SCALOP-2 is a multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer. Divided into two stages, the trial includes a safety run-in which will determine the Mazimum Tolerated Dose (MTD) of nelfinavir in combination with capecitabine and 50.4Gy of radioherapy, and establish the dose to take forward to Stage 2. Stage 2 comprises of an open-label randomised clinical trial, designed with a 2 X 2 factorial + a chemotherapy-only arm + an observational cohort.
Stage 1 sites currently open for recruitment are Addenbrooke's Hospital Cambridge, Bristol Haematology and Oncology Centre, Churchill Hospital Oxford, Royal Free Hospital London, Royal Surrey County Hospital, St James' University Hospital Leeds and Velindre, Cardiff.
Stage 1 Study Schema